Search

everythinglearnresearchcommunity

for

Search:↓

The document concludes that there are various treatments for different types of alopecia, but more research is needed for evidence-based treatments.

Topical anthralin helped regrow hair in mice with a condition similar to human alopecia.

Alopecia Areata is a hair loss condition affecting all genders, often linked to other diseases, with treatments available but varying success rates.

Alopecia areata is an unpredictable autoimmune hair loss condition, treated based on severity, with half of patients regrowing hair within a year without treatment.

Alopecia areata causes sudden hair loss, often resolves within a year, but can recur.

Topical immunotherapy can treat alopecia areata, but its effectiveness varies and the exact mechanism is unclear.

Combining diphenylcyclopropenone with anthralin is more effective for hair regrowth in alopecia areata than using diphenylcyclopropenone alone, but may cause more side effects.

Contact immunotherapy can cause vitiligo in patients with autoimmune conditions.

DPCP alone is more effective and safer for treating chronic extensive alopecia areata than combining it with anthralin.

Combining imiquimod with diphenylcyclopropenone may improve treatment outcomes for alopecia areata patients who don't respond to diphenylcyclopropenone alone.

Higher granulysin levels in the blood are linked to more severe hair loss in alopecia areata patients, and these levels decrease after effective treatment.

DPCP is effective for treating severe alopecia areata, but relapse is common.

Alopecia areata causes hair loss, has no cure, and various treatments exist.

Alopecia areata is an autoimmune disease with genetic links, treatable with certain medications, and can affect mental health.

Wharton's jelly-derived stem cells were safely used to treat four alopecia patients, resulting in hair regrowth in all of them.

Alopecia areata patients have higher levels of IL-6 and TNF-α.

The document concludes that various childhood hair and nail disorders exist, some may improve on their own, and advances in genetics and immunology could enhance treatment and counseling.

Poor response to topical immunotherapy in alopecia areata patients is linked to impaired cell responses.

Alopecia areata involves specific T-cells, unlike androgenetic alopecia.

Alopecia areata can cause unpredictable hair loss, and treatments like corticosteroids and minoxidil may help but have varying side effects.

Old treatments for other skin conditions showed promise for hair regrowth in mice with a hair loss condition.

Alopecia areata shows a unique type 1 interferon signature, suggesting potential treatment by targeting this pathway.

The document concludes that ongoing research using animal models is crucial for better understanding and treating Alopecia Areata.

A woman developed hair loss after starting a treatment with adalimumab, suggesting this medication might cause hair loss.

People with alopecia areata have higher insulin resistance.

Faulty inflammasome activation may lead to autoimmune skin diseases and could be a target for new treatments.

T-cells in alopecia areata scalp show abnormal regulation, leading to less inflammation.

Alopecia areata is an autoimmune disease where T cells attack hair follicles.

Certain natural and synthetic compounds may help treat inflammatory skin diseases by targeting a specific signaling pathway.

Understanding the cause of bitemporal hair loss is key to deciding the right treatment.